MedPage Today July 25, 2018
-Agency heads tout advances in clinical trials, cancer research, and genomics
Top brass from the FDA and the NIH shared their progress in implementing the 21st Century Cures Act during a House hearing Wednesday.
The Cures Act aims to hasten the development and discovery of new treatments for hard-to-treat diseases, and was signed into law in December 2016. It authorized $6.3 billion for funding basic science, streamlining the FDA’s review process, and addressing the opioids epidemic.
At the hearing, lawmakers asked for clarification on reports that money appropriated for Cures programs was being spent on addressing the immigration crisis at the southern U.S. border. Some reports suggested that dollars had been redirected to the Office...
Today's Sponsors
Today's Sponsor